CircABCC1 promotes the development of glioma by sponging miR‐591 and modulating high‐mobility group A2

2022 ◽  
Author(s):  
Lei Wang ◽  
Ying Tan ◽  
Jun Chen ◽  
Ziyu Zhu ◽  
Yuting Zhu ◽  
...  
Keyword(s):  
High Mobility ◽  
High Mobility Group

High Mobility Group Protein HMG-R

2020 ◽  
Author(s):  
Keyword(s):  
High Mobility ◽  
High Mobility Group ◽  
High Mobility Group Protein ◽  
Group Protein

Histidine-Rich Glycoprotein Inhibits High Mobility Group Box 1-Mediated Pathways in Vascular Endothelial Cells

2019 ◽  
Author(s):  
Shangze Gao ◽  
Hidenori Wake ◽  
Masakiyo Sakaguchi ◽  
Dengli Wang ◽  
Youhei Takahashi ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Vascular Endothelial Cells ◽  
High Mobility ◽  
High Mobility Group ◽  
Vascular Endothelial

Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease

2016 ◽  
Vol 17 (8) ◽  
pp. 762-775 ◽  
Author(s):  
Neelam Lohani ◽  
Moganty R. Rajeswari
Keyword(s):  
Dna Binding ◽  
Human Health ◽  
High Mobility ◽  
High Mobility Group ◽  
Health And Disease

High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics

2019 ◽  
Vol 20 (14) ◽  
pp. 1474-1485 ◽  
Author(s):  
Eyaldeva C. Vijayakumar ◽  
Lokesh Kumar Bhatt ◽  
Kedar S. Prabhavalkar
Keyword(s):  
Myocardial Infarction ◽  
Vagus Nerve Stimulation ◽  
Nuclear Protein ◽  
Therapeutic Potential ◽  
High Mobility ◽  
Dna Binding Protein ◽  
High Mobility Group ◽  
Eukaryotic Cells ◽  
Hmgb1 Protein

High mobility group box-1 (HMGB1) mainly belongs to the non-histone DNA-binding protein. It has been studied as a nuclear protein that is present in eukaryotic cells. From the HMG family, HMGB1 protein has been focused particularly for its pivotal role in several pathologies. HMGB-1 is considered as an essential facilitator in diseases such as sepsis, collagen disease, atherosclerosis, cancers, arthritis, acute lung injury, epilepsy, myocardial infarction, and local and systemic inflammation. Modulation of HMGB1 levels in the human body provides a way in the management of these diseases. Various strategies, such as HMGB1-receptor antagonists, inhibitors of its signalling pathway, antibodies, RNA inhibitors, vagus nerve stimulation etc. have been used to inhibit expression, release or activity of HMGB1. This review encompasses the role of HMGB1 in various pathologies and discusses its therapeutic potential in these pathologies.

Sign in / Sign up

Export Citation Format

Share Document